Liraglutide Phase 3 Trial in Obese Women With PCOS Completes

ClinicalTrials.gov recorded primary completion on 30 November 2025 for a completed Phase 3 study of liraglutide in obese, infertile women with polycystic ovary syndrome. The trial enrolled 183 participants and compared liraglutide with metformin for hormonal, metabolic and clinical effects.

Background

The study focused on women with polycystic ovary syndrome, described in the registry summary as PCOs, who were experiencing infertility and obesity. Its stated aim was to compare liraglutide and metformin across hormonal, metabolic and clinical effects. The supplied record does not provide additional information about liraglutide’s drug class, mechanism, prior approvals, or the prevalence of polycystic ovary syndrome.

Trial design

This was a Phase 3 clinical study listed as completed in the registry. It enrolled 183 participants and evaluated women with polycystic ovary syndrome. The registered interventions were liraglutide and metformin. The brief study summary identifies the population as infertile women with PCOs and specifies hormonal, metabolic and clinical effects as the areas of comparison.

The supplied data do not list a primary outcome measurement, follow-up time point, allocation method, or comparator dosing information. They also do not provide a numerical outcome analysis or an adverse-event summary.

What this means

Completion of the trial indicates that the Phase 3 study comparing liraglutide with metformin has finished according to the ClinicalTrials.gov record. The available data establish the study population, enrollment, interventions and stated purpose, but they do not show whether liraglutide performed better than metformin on hormonal, metabolic or clinical measures.

No efficacy values, safety findings, confidence intervals or p-values are included in the supplied record. The completion event therefore does not, by itself, establish a treatment benefit, a safety conclusion, or a new regulatory indication.

Source

Source: ClinicalTrials.gov, completed trial record for NCT05965908, with primary completion dated 30 November 2025. The registry record is available at clinicaltrials.gov/study/NCT05965908.